Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer
Guidance for Transmittal 136, dated November 2, 2011, is being rescinded and replaced with Transmittal140, dated January 6, 2012. The changes include additional clarification under the Policy section regarding payment for administration of PROVENGE®, deletion of original business requirements (BRs) 8, 8.1, 9, and 9.1 relating to Common Working File frequency edits, and a date change from April 2, 2012, to July 2, 2012, in current BR 9as it relates to Pub. 100-04 (BR). Language in current BR 7 has been revised to align with the policy changes made that allow separate payment for the cost of administration. All other information remains the same.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: November 02, 2011
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.